JNJ (Johnson & Johnson)
Insider Trading Activity
Every open-market purchase and sale reported by JNJ officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-04 | Timothy Schmid | EVP, WW Chair, MedTech | MIXED | — | — |
| 2026-08-18 | Jennifer L Taubert | EVP, WWC. Innovative Medicine | MIXED | — | — |
| 2026-08-14 | Joaquin Duato | CEO and Chairman of the Board | MIXED | — | — |
| 2026-08-07 | Elizabeth Forminard | EVP, Chief Legal Officer | MIXED | — | — |
| 2026-08-07 | Joaquin Duato | CEO and Chairman of the Board | Sell | — | — |
| 2026-08-07 | Joaquin Duato | CEO and Chairman of the Board | Sell | — | — |
| 2026-08-07 | Elizabeth Forminard | EVP, Chief Legal Officer | MIXED | — | — |
| 2026-07-21 | Vanessa Broadhurst | EVP, Global Corp Affairs | MIXED | — | — |
| 2023-07-27 | William Hait | See Remarks | MIXED | — | — |
| 2023-07-27 | Peter Fasolo | Exec VP, Chief HR Officer | Sell | — | — |
| 2023-06-14 | Kathryn E Wengel | EVP, Chief TO and Risk Officer | Sell | — | — |
| 2023-06-08 | MARILLYN A HEWSON | Director | A | — | — |
| 2023-05-25 | Joseph J Wolk | Exec VP, CFO | G | — | — |
| 2023-05-02 | Darius Adamczyk | Director | A | — | — |
| 2023-05-02 | D SCOTT DAVIS | Director | A | — | — |
| 2023-05-02 | Mary C Beckerle | Director | A | — | — |
| 2023-05-02 | Jennifer A Doudna | Director | A | — | — |
| 2023-05-02 | Hubert Joly | Director | A | — | — |
| 2023-05-02 | Mark B. McClellan | Director | A | — | — |
| 2023-05-02 | MARILLYN A HEWSON | Director | A | — | — |
| 2023-05-02 | Paula A Johnson | Director | A | — | — |
| 2023-05-02 | ANNE M MULCAHY | Director | A | — | — |
| 2023-05-02 | MARK A WEINBERGER | Director | A | — | — |
| 2023-05-02 | Nadja West | Director | A | — | — |
| 2023-05-02 | JOHN C REED | EVP, Pharmaceuticals R&D | A | — | — |
| 2023-03-09 | MARILLYN A HEWSON | Director | A | — | — |
| 2023-03-09 | A. Eugene Washington | Director | A | — | — |
| 2023-03-08 | James D. Swanson | See Remarks | Sell | — | — |
| 2023-02-15 | Vanessa Broadhurst | EVP, Global Corp Affairs | MIXED | — | — |
| 2023-02-15 | Elizabeth Forminard | Executive VP, General Counsel | MIXED | — | — |
| 2023-02-15 | Robert J Decker | VP Corporate Controller | MIXED | — | — |
| 2023-02-15 | Joaquin Duato | CEO and Chairman of the Board | MIXED | — | — |
| 2023-02-15 | Peter Fasolo | Exec VP, Chief HR Officer | MIXED | — | — |
| 2023-02-15 | William Hait | See Remarks | MIXED | — | — |
| 2023-02-15 | Ashley McEvoy | EVP, WW Chair, MedTech | MIXED | — | — |
| 2023-02-15 | Thibaut Mongon | Exec VP, WW Chair, Cons Health | MIXED | — | — |
| 2023-02-15 | James D. Swanson | See Remarks | MIXED | — | — |
| 2023-02-15 | Jennifer L Taubert | EVP, WW Chair, Pharmaceuticals | MIXED | — | — |
| 2023-02-15 | Kathryn E Wengel | EVP, Chief TO and Risk Officer | MIXED | — | — |
| 2023-02-15 | Joseph J Wolk | Exec VP, CFO | MIXED | — | — |
| 2023-02-14 | James D. Swanson | See Remarks | MIXED | — | — |
| 2023-02-14 | Peter Fasolo | Exec VP, Chief HR Officer | MIXED | — | — |
| 2023-02-14 | Vanessa Broadhurst | EVP, Global Corp Affairs | MIXED | — | — |
| 2023-02-14 | Robert J Decker | VP Corporate Controller | MIXED | — | — |
| 2023-02-14 | Thibaut Mongon | Exec VP, WW Chair, Cons Health | MIXED | — | — |
| 2023-02-14 | William Hait | See Remarks | MIXED | — | — |
| 2023-02-14 | Elizabeth Forminard | Executive VP, General Counsel | MIXED | — | — |
| 2023-02-14 | Ashley McEvoy | EVP, WW Chair, MedTech | MIXED | — | — |
| 2023-02-14 | Jennifer L Taubert | EVP, WW Chair, Pharmaceuticals | MIXED | — | — |
| 2023-02-14 | Joseph J Wolk | Exec VP, CFO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chairman, CEO | 1,133,871 | — |
| — | CEO and Chairman of the Board | 379,300 | — |
| — | Chairman/CEO | 354,009 | — |
| — | Vice Chair, Exec Committee | 289,864 | — |
| — | EVP, WWC. Innovative Medicine | 209,451 | — |
| — | Vice Chairman | 209,056 | — |
| — | Exec VP, Finance; CFO | 177,871 | — |
| — | Exec VP, General Counsel | 160,121 | — |
| — | VP, General Counsel | 143,921 | — |
| — | Member, Executive Committee | 108,014 | — |
| — | Corporate Controller | 102,996 | — |
| — | Exec VP, Chief HR Officer | 102,696 | — |
| — | See Remarks | 102,445 | — |
| — | Exec VP, Group WW Chairman | 83,349 | — |
| — | VP, Strategy & Growth | 66,487 | — |
| — | EVP, Chief TO and Risk Officer | 66,214 | — |
| — | Exec VP, WW Chair, Cons Health | 65,915 | — |
| — | EVP, Global Corp Aff & CCO | 63,445 | — |
| — | Member, Executive Committee | 62,762 | — |
| — | EVP, WW Chair, MedTech | 62,282 | — |
| — | Vice Chairman | 61,958 | — |
| — | Exec VP, CFO | 52,345 | — |
| — | EVP, Pharm, R&D | 45,300 | — |
| — | Exec VP, WW Chair, Med Devices | 43,726 | — |
| — | Member, Executive Committee | 37,658 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the JNJ quote page; the site-wide leaderboard is on the insider transactions hub.